Paper: Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Glofitamab, a CD3-CD20 bi-specific T cell engager, was combined with polatuzumab, a cd79b antibody drug conjugate, in a phase I/II study in 44 patients with relapsed/refractory DLCBL. CRS was common (55%) but limited to grade 1 and 2. 52% had serious adverse events. 18% were high grade BCL, and 64% were refractory to the last therapy. ORR was 73% and CR rate was 51.5. As polatuzumab is moving towards front line it will be unclear if we can expect the same response rates by the time this combination completes a phase III.
